Iraklii Buziashvili, MD
Endocrinology, Diabetes & Metabolism · Brooklyn, NYNPI 1043593940
Payments from drug & device makers
Across 540 payments — averaging $192.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$49K
- Lilly USA, LLC$46K
- Johnson & Johnson$2K
- Amgen$2K
- Sanofi-aventis U.S. LLC$1K
- AstraZeneca$1K
- plus $3K from 28 others
What the payments were for
- Consulting fees$3750%
- Speaking & faculty fees$86,04083%
- Travel & lodging$3,1413%
- Food & beverage$14,25014%
- Education$880%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 127 | $49,063 |
| Lilly USA, LLC | 93 | $45,643 |
| Johnson & Johnson | 8 | $2,394 |
| Amgen(2 entities) | 63 | $1,522 |
| Sanofi-aventis U.S. LLC | 57 | $1,155 |
| AstraZeneca | 47 | $1,024 |
| Bayer | 19 | $522 |
| Novo Nordisk | 16 | $331 |
| AbbVie | 13 | $302 |
| Merck | 14 | $220 |
| IBSA Pharma Inc. | 15 | $187 |
| Xeris Pharmaceuticals, Inc. | 8 | $173 |
| Antares Pharma, Inc. | 8 | $159 |
| Amryt Pharma Holdings Ltd | 7 | $158 |
| Madrigal Pharmaceuticals | 4 | $136 |
| Corcept Therapeutics | 5 | $123 |
| Novartis | 6 | $121 |
| Amarin Pharma, Inc. | 5 | $96 |
| Medtronic | 3 | $86 |
| Insulet Corporation | 3 | $70 |
| Ultragenyx Pharmaceutical Inc. | 2 | $46 |
| Amneal Pharmaceuticals LLC | 2 | $42 |
| Vistapharm, Inc. | 2 | $38 |
| Dexcom, Inc. | 2 | $38 |
| Cequr Corporation | 1 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Tandem Diabetes Care, Inc. | 1 | $31 |
| Radius Health, Inc. | 1 | $28 |
| Ascendis Pharma Endocrinology Inc | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Kowa Pharmaceuticals America, Inc. | 1 | $20 |
| Intuity Medical Inc | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Almatica Pharma LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$103,894 in reported general payments places this provider in the 90th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 1,704 | $1,845,115 |
| TrulicityDulaglutide | 1,227 | $1,329,226 |
| OzempicSemaglutide | 778 | $794,589 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 1,022 | $738,723 |
| JardianceEmpagliflozin | 919 | $661,589 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 347 | $254,741 |
| ProliaDenosumab | 99 | $164,169 |
| FarxigaDapagliflozin Propanediol | 217 | $149,537 |
| Xigduo XrDapaglifloz Propaned/Metformin | 208 | $142,337 |
| Metformin Er GastricMetformin Hcl | 47 | $88,287 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 348 | $80,054 |
| Tresiba Flextouch U-200Insulin Degludec | 107 | $62,258 |
| Cinacalcet Hcl | 88 | $61,886 |
| Repatha SureclickEvolocumab | 90 | $54,940 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 73 | $49,109 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $45,643 | $3,174,3402,931 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance, Tradjenta, Synjardy | $49,063 | $1,440,5472,008 claims |
| Novo NordiskOzempic, Rybelsus | $331 | $835,100816 claims |
| AmgenProlia | $1,522 | $164,16999 claims |
| AstraZenecaFarxiga | $1,024 | $149,537217 claims |
| MerckJanuvia, Janumet Xr, Janumet | $220 | $75,85898 claims |
| AbbVieLinzess, Creon, Synthroid | $302 | $63,474342 claims |
| BayerKerendia | $522 | $22,59933 claims |
| Antares Pharma, Inc.Xyosted | $159 | $16,36327 claims |
| Johnson & JohnsonInvokana | $2,394 | $13,15819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in Brooklyn
- Robert SilverBrooklyn$1.3M
- Alexander PerkelvaldBrooklyn$323K
- John LeffBrooklyn$248K
- Matvey BrokhinBrooklyn$243K
- Matin SharafatkhahBrooklyn$235K
- Robert BuschAlbany$9.1M
- Anastasios ManessisNew York$4.4M
- Ruth WeinstockSyracuse$3.1M
- Adi CohenNew York$2.5M
- Ajay ChaudhuriBuffalo$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.